FDA expands approval of non-stimulant ADHD drug to adults
The Food and Drug Administration (FDA) has expanded its approval of a non-stimulant drug for ADHD, the first in about 20 years, to include adults along with children. Viloxazine, sold commercially as Qelbree in extended-release capsules, has been approved to help treat ADHD in adults 18 and over, its maker, Supernus Pharmaceuticals, announced. Qelbree was …
FDA expands approval of non-stimulant ADHD drug to adults Read More »